Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Market Movers
TipRanks Momentum Index
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
Top ETFs by Upside
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Value
New
Ideas
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Most Visited Websites
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Economic Indicators
Inflation Rate
Unemployment Rate
Class Actions
Tools
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Screeners
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Dividends
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Experts
Portfolio
News
Enterprise Solutions
Education
Personal Finance
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Advertise with Us
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Arrived
EquityMultiple
Follow Us
More
Plans
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Screeners
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Premium Newsletters
Smart Value
Research Tools
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Calculators
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividends
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Calculators
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Plans & Pricing
More
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Log Out
SRPT
Stock Latest News
The Fly
Sarepta price target lowered to $80 from $105 at Scotiabank
7d ago
SRPT
Premium
Market News
Patient Fatality Forces Reality Check on Sarepta Therapeutics Stock (SRPT)
8d ago
DYN
NVS
Premium
The Fly
Sarepta weakness ‘compelling’ buying opportunity, says Mizuho
8d ago
SRPT
Premium
Ratings
Sell Rating on Sarepta Therapeutics Due to Safety Concerns and Revenue Challenges for ELEVIDYS
8d ago
SRPT
Premium
Ratings
Sarepta Therapeutics’ Elevidys: Maintaining a Buy Rating Amid Safety Concerns and Low Adverse Effect Incidence
8d ago
SRPT
Premium
The Fly
Sarepta price target lowered to $99 from $124 at Deutsche Bank
8d ago
SRPT
Premium
The Fly
Sarepta stock reaction overdone, says Barclays
8d ago
SRPT
Premium
The Fly
Sarepta update could boost enrollment in Regenxbio study, says Morgan Stanley
8d ago
RGNX
SRPT
Premium
The Fly
Sarepta news opens door for Regenxbio over risk/benefit profile, says Leerink
8d ago
RGNX
SRPT
Premium
The Fly
Analysts remain optimistic about Elevidys after Sarepta reports patient death
8d ago
RGNX
SLDB
Premium
Ratings
Buy Rating Maintained for Sarepta Therapeutics Despite Safety Concerns with Elevidys
8d ago
SRPT
Premium
The Fly
Leerink says Sarepta stock reaction ‘overdone,’ remains positive on Elevidys
8d ago
RGNX
SLDB
Premium
Ratings
Sami Corwin Maintains Positive Outlook on Sarepta Despite Elevidys Incident, Highlights Future Growth Potential
8d ago
SRPT
Premium
The Fly
Sarepta shares to dislocate from fundamentals after patient death, says JPMorgan
8d ago
SRPT
Premium
The Fly
BofA says Elevidys risk-reward favorable despite Sarepta report of patient death
9d ago
SRPT
Premium
Ratings
Optimistic Buy Rating for Sarepta Therapeutics Amidst DMD Treatment Challenges and Safety Concerns
9d ago
SRPT
Premium
The Fly
Patient death shouldn’t spell the end for Sarepta’s Elevidys, says RBC Capital
9d ago
SRPT
Premium
The Fly
Jefferies expects Sarepta weakness given uncertainty around Elevidys safety
9d ago
SRPT
Premium
The Fly
Morning Movers: Sarepta slumps after death following Elevidys use
9d ago
BTM
BTU
Premium
The Fly
Sarepta falls after notifying of patient death following treatment with Elevidys
9d ago
SRPT
Premium
The Fly
Tesla upgraded, Coinbase initiated: Wall Street’s top analyst calls
19d ago
W
AL
Premium
The Fly
Sarepta initiated with a Sector Perform at Scotiabank
20d ago
SRPT
Show More
Trending
Indices
Stocks
ETFs
Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >
You need to enable JavaScript to run this app.
